Orion Pharma Limited (DSE:ORIONPHARM)
26.60
+0.40 (1.53%)
At close: May 5, 2026
Orion Pharma Balance Sheet
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 81.85 | 72.1 | 147.73 | 130.11 | 106.13 | 414.99 |
Short-Term Investments | 66.49 | 54.18 | 45.82 | 38.68 | 31.83 | 23.62 |
Cash & Short-Term Investments | 148.34 | 126.28 | 193.55 | 168.79 | 137.97 | 438.61 |
Cash Growth | 9.69% | -34.75% | 14.67% | 22.34% | -68.54% | -58.38% |
Accounts Receivable | 15,345 | 4,390 | 4,210 | 5,584 | 6,796 | 3,943 |
Other Receivables | - | 10,656 | 10,267 | 9,811 | 8,109 | 8,458 |
Receivables | 15,345 | 15,046 | 14,477 | 15,395 | 14,905 | 12,401 |
Inventory | 1,077 | 1,505 | 1,699 | 1,614 | 1,660 | 1,411 |
Prepaid Expenses | - | - | 0.11 | 1.1 | 26.19 | 43.84 |
Other Current Assets | 923.75 | 859.62 | 1,045 | 1,897 | 2,026 | 1,928 |
Total Current Assets | 17,495 | 17,537 | 17,415 | 19,076 | 18,755 | 16,223 |
Property, Plant & Equipment | 32,247 | 30,937 | 28,951 | 26,424 | 23,009 | 19,856 |
Long-Term Investments | 7,401 | 7,322 | 8,067 | 7,440 | 6,343 | 6,254 |
Other Long-Term Assets | -0 | - | - | - | - | - |
Total Assets | 57,144 | 55,796 | 54,433 | 52,940 | 48,107 | 42,333 |
Accounts Payable | 7,161 | 6,710 | 6,136 | 6,259 | 7,301 | 4,231 |
Accrued Expenses | 631.26 | 278.28 | 298.44 | 270.03 | 265.44 | 232.48 |
Short-Term Debt | 409.59 | 493.7 | 556.18 | 547.82 | 563.9 | 564.32 |
Current Portion of Long-Term Debt | - | - | 67.35 | 490.5 | 387.47 | 274.33 |
Current Portion of Leases | 14.02 | 14.93 | 13.94 | 23.91 | 31.66 | 36.42 |
Current Income Taxes Payable | - | 321.16 | 304.49 | 435.26 | 398.62 | 262.75 |
Other Current Liabilities | 284.42 | 645.99 | 390.05 | 1,444 | 488.23 | 406.06 |
Total Current Liabilities | 8,500 | 8,464 | 7,766 | 9,470 | 9,437 | 6,008 |
Long-Term Debt | 26,583 | 25,137 | 23,111 | 20,808 | 17,601 | 15,930 |
Long-Term Leases | 32.16 | 31.69 | 13.71 | 26.35 | 35.27 | 39.9 |
Long-Term Deferred Tax Liabilities | 453.26 | 402.12 | 315.43 | 157.7 | 122.25 | 138.28 |
Other Long-Term Liabilities | 143.41 | 143.41 | 143.41 | 143.41 | 143.41 | 143.41 |
Total Liabilities | 35,712 | 34,178 | 31,350 | 30,606 | 27,338 | 22,259 |
Common Stock | 2,340 | 2,340 | 2,340 | 2,340 | 2,340 | 2,340 |
Additional Paid-In Capital | 8,017 | 8,017 | 8,017 | 8,017 | 8,017 | 8,017 |
Retained Earnings | 6,639 | 6,857 | 7,499 | 7,400 | 6,978 | 6,401 |
Comprehensive Income & Other | 3,002 | 2,932 | 3,683 | 3,067 | 1,978 | 1,905 |
Total Common Equity | 19,998 | 20,146 | 21,540 | 20,824 | 19,313 | 18,663 |
Minority Interest | 1,434 | 1,472 | 1,543 | 1,510 | 1,456 | 1,412 |
Shareholders' Equity | 21,432 | 21,618 | 23,083 | 22,334 | 20,769 | 20,074 |
Total Liabilities & Equity | 57,144 | 55,796 | 54,433 | 52,940 | 48,107 | 42,333 |
Total Debt | 27,039 | 25,677 | 23,762 | 21,897 | 18,619 | 16,844 |
Net Cash (Debt) | -26,891 | -25,539 | -23,552 | -21,700 | -18,446 | -16,377 |
Net Cash Per Share | -114.92 | -109.14 | -100.65 | -92.74 | -78.83 | -69.99 |
Filing Date Shares Outstanding | 234 | 234 | 234 | 234 | 234 | 234 |
Total Common Shares Outstanding | 234 | 234 | 234 | 234 | 234 | 234 |
Working Capital | 8,995 | 9,073 | 9,648 | 9,606 | 9,318 | 10,216 |
Book Value Per Share | 85.46 | 86.09 | 92.05 | 88.99 | 82.53 | 79.76 |
Tangible Book Value | 19,998 | 20,146 | 21,540 | 20,824 | 19,313 | 18,663 |
Tangible Book Value Per Share | 85.46 | 86.09 | 92.05 | 88.99 | 82.53 | 79.76 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.